P8. Why do symptomatic breast cancer patients slip through breast screening programs?

2012 ◽  
Vol 38 (11) ◽  
pp. 1107-1108
Author(s):  
William Carr ◽  
Keith Callanan
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Screening ◽  
Breast Cancer Patients ◽  
Screening Programs ◽  
Symptomatic Breast Cancer ◽  
Symptomatic Breast

scholarly journals Reasons symptomatic breast cancer patients delay seeking medical care

2019 ◽  
Vol 2019 ◽  
Author(s):  
Jacqueline Heath ◽  
Melody Paulishak ◽  
Claudia Kasales ◽  
Jane Schubart ◽  
Rena Kass
Keyword(s):  
Breast Cancer ◽  
Medical Care ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Symptomatic Breast Cancer ◽  
Symptomatic Breast

scholarly journals Previously diagnosed multiple primary malignancies in patients with breast carcinoma in Western Sweden between 2007 and 2018

2020 ◽  
Vol 184 (1) ◽  
pp. 221-228
Author(s):  
Jenny Nyqvist ◽  
Toshima Z. Parris ◽  
Khalil Helou ◽  
Elisabeth Kenne Sarenmalm ◽  
Zakaria Einbeigi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Registry ◽  
University Hospital ◽  
Breast Cancer Patients ◽  
Gastrointestinal Malignancies ◽  
Screening Programs ◽  
Multiple Primary Malignancies ◽  
Multiple Primary ◽  
Swedish Cancer Registry

Abstract Purpose Multiple primary malignancies (MPMs) caused by breast cancer treatment are well described, but only few studies to date describe which other previous primary malignancies (OPPMs) occur before breast cancer. The purpose of the present study was to evaluate the prevalence of OPPMs in patients with breast cancer between 2007 and 2018 in Western Sweden. Methods Patient selection was performed using both pathology reports at Sahlgrenska University Hospital (Sweden) and the Swedish Cancer Registry. All newly diagnosed breast cancer patients were screened for presence of OPPM. Results In total, 8031 breast cancer patients were diagnosed at Sahlgrenska University Hospital between 2007 and 2018. The prevalence of breast cancer patients with OPPMs (n = 414) increased from on average 2.6% to 8.2% during this 12-year period and ranged from 17 to 59 patients annually. The most striking increase in prevalence was found among the gynecological tumors (endometrium and ovarian adenocarcinomas), malignant melanomas and gastrointestinal malignancies. These findings were validated using data of the Swedish Cancer Registry. Conclusions The overall survival rates for cancer patients have improved tremendously during the past 40 years, in part due to individually tailored therapies and screening programs. Our study revealed an increasing trend of OPPMs in breast cancer patients.

Use of surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF-MS) to detect breast cancer markers in serum

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22133-e22133
Author(s):  
D. Boehm ◽  
A. Lebrecht ◽  
R. Schwirz ◽  
K. Keller ◽  
M. Schmidt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Protein Profiling ◽  
Breast Cancer Patients ◽  
Screening Programs ◽  
Healthy Women ◽  
Metastatic Relapse ◽  
Protein Chips ◽  
Detect Breast Cancer ◽  
Tof Ms

e22133 Background: Breast cancer is one of the most frequent and deadly cancers worldwide. Although the survival of patients has increased over the last decades, many patients die from metastatic relapse. Progresses in screening or early diagnosis will improve survival of breast cancer. Breast cancer has never had any good serum tumor markers. Therefore, we developed and evaluated a proteomics approach to search for new biomarkers in serum of breast cancer patients. Methods: Blood samples of 50 women with breast cancer (CA) and 50 healthy women (CTRL), matched to the age, were drawn prior to surgery. We used SELDI-TOF-MS for protein profiling with three different active surfaces of the protein chips: cationic exchanger (CM-10), hydrophobic surface (H50) and a strong anion exchange surface (Q10) with different binding properties. Data were analyzed by multivariate statistical techniques and artificial neural networks. Results: SELDI-TOF- MS could discriminate between serum of breast cancer patients and healthy women. We could generate a statistic significant (p<0.001) panel with 15 biomarkers resulting of multiple peaks with different molecular weights. The diagnostic pattern could differentiate CA from CRTL with specificity of 77% and sensitivity of 85% in serum. Conclusions: In this study we could exemplify SELDI-TOF-MS as a potential screening method to detect breast cancer patients by serum analysis. The protein chip technology could greatly facilitate the discovery of new and better biomarkers in breast cancer patients. This promising approach provides a high sensitivity and specificity by a less invasive method similar to mammography that is used in screening programs. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document